Evidence map›Paper›PMID 25184286›Full record

ArticlePloS one2014

Evidence that multiple defects in lipid regulation occur before hyperglycemia during the prodrome of type-2 diabetes.

Simon G Anderson, Warwick B Dunn, Moulinath Banerjee, Marie Brown, David I Broadhurst, Royston Goodacre, Garth J S Cooper, Douglas B Kell, J Kennedy Cruickshank

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Risky Early Family Environment and Genetic Associations with Adult Metabolic Dysregulation.International journal of environmental research and public health · 2022
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Simon G AndersonInstitute of Cardiovascular Sciences, Core Technology Facility, The University of Manchester, Manchester, United Kingdom.
Warwick B DunnManchester Centre for Integrative Systems Biology, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom; Centre for Advanced Discovery & Experimental Therapeutics (CADET), Central Manchester NHS Foundation Trust and School of Biomedicine, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom; School of Biosciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom.
Moulinath BanerjeeInstitute of Cardiovascular Sciences, Core Technology Facility, The University of Manchester, Manchester, United Kingdom.
Marie BrownManchester Centre for Integrative Systems Biology, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
David I BroadhurstManchester Centre for Integrative Systems Biology, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom; Division of General Internal Medicine, Department of Medicine, 4126A Katz Group Centre for Pharmacy & Health, University of Alberta, Edmonton, Alberta, Canada.
Royston GoodacreManchester Centre for Integrative Systems Biology, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
Garth J S CooperCentre for Advanced Discovery & Experimental Therapeutics (CADET), Central Manchester NHS Foundation Trust and School of Biomedicine, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom; Maurice Wilkins Centre for Molecular Biodiscovery, Faculty of Science, University of Auckland, Auckland, New Zealand; Department of Pharmacology, University of Oxford, Oxford, United Kingdom.
Douglas B KellManchester Centre for Integrative Systems Biology, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
J Kennedy CruickshankInstitute of Cardiovascular Sciences, Core Technology Facility, The University of Manchester, Manchester, United Kingdom; Diabetes & Nutritional Sciences Division, King's College London, London, United Kingdom.
University of Manchester · GBUniversity of Alberta · CAUniversity of Auckland · NZUniversity of Birmingham · GB

Funding

Biotechnology and Biological Sciences Research Council BB/C008219Biotechnology and Biological Sciences Research Council BB/G010250/1Medical Research Council MR/L010445/1
6 · The paper itself

Abstract

backgroundBlood-vessel dysfunction arises before overt hyperglycemia in type-2 diabetes (T2DM). We hypothesised that a metabolomic approach might identify metabolites/pathways perturbed in this pre-hyperglycemic phase. To test this hypothesis and for specific metabolite hypothesis generation, serum metabolic profiling was performed in young women at increased, intermediate and low risk of subsequent T2DM.

methodsParticipants were stratified by glucose tolerance during a previous index pregnancy into three risk-groups: overt gestational diabetes (GDM; n = 18); those with glucose values in the upper quartile but below GDM levels (UQ group; n = 45); and controls (n = 43, below the median glucose values). Follow-up serum samples were collected at a mean 22 months postnatally. Samples were analysed in a random order using Ultra Performance Liquid Chromatography coupled to an electrospray hybrid LTQ-Orbitrap mass spectrometer. Statistical analysis included principal component (PCA) and multivariate methods.

findingsSignificant between-group differences were observed at follow-up in waist circumference (86, 95%CI (79-91) vs 80 (76-84) cm for GDM vs controls, p<0.05), adiponectin (about 33% lower in GDM group, p = 0.004), fasting glucose, post-prandial glucose and HbA1c, but the latter 3 all remained within the 'normal' range. Substantial differences in metabolite profiles were apparent between the 2 'at-risk' groups and controls, particularly in concentrations of phospholipids (4 metabolites with p ≤ 0.01), acylcarnitines (3 with p ≤ 0.02), short- and long-chain fatty acids (3 with p<  = 0.03), and diglycerides (4 with p ≤ 0.05).

interpretationDefects in adipocyte function from excess energy storage as relatively hypoxic visceral and hepatic fat, and impaired mitochondrial fatty acid oxidation may initiate the observed perturbations in lipid metabolism. Together with evidence from the failure of glucose-directed treatments to improve cardiovascular outcomes, these data and those of others indicate that a new, quite different definition of type-2 diabetes is required. This definition would incorporate disturbed lipid metabolism prior to hyperglycemia.

Indexed as

Lipid MetabolismMetabolomeAdiponectinAdipose TissueAdultBlood GlucoseCarnitineDiabetes, GestationalDiabetes Mellitus, Type 2DiglyceridesFastingFemaleFollow-Up StudiesGlucose Tolerance TestHumansHyperglycemiaacylcarnitineAdiponectinBlood GlucoseCarnitineDiglyceridesInsulinPhospholipids

Identifiers

PMID25184286
PMCPMC4153569
OpenAlexW2143568134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.